Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Patients with interstitial lung disease can develop a progressive fibrosing phenotype characterised by an irreversible, progressive decline in lung function despite treatment. Current therapies slow, but do not reverse or stop, disease progression and are associated with side-effects that can cause...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European respiratory review 2023-03, Vol.32 (167), p.220206
Hauptverfasser:	Kolb, Martin, Crestani, Bruno, Maher, Toby M
Format:	Artikel
Sprache:	eng
Schlagworte:	Cyclic Nucleotide Phosphodiesterases, Type 4 - pharmacology Disease Progression Humans Idiopathic Pulmonary Fibrosis Life Sciences Lung Lung Diseases, Interstitial Phosphodiesterase 4 Inhibitors - adverse effects Reviews
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!